×

Before you go!

Sign up for the FREE weekly email newsletter from the publishers of American Nurse Today. You’ll get breaking news features, exclusive investigative stories, and more — delivered to your inbox.

Sign up today!

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
Drugs and Devices

FDA allows marketing of device to help assess children and teens for ADHD

On June 15, the U.S. Food and Drug Administration (FDA) allowed marketing of the first medical device based on brain function to help assess attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old. The Neuropsychiatric EEG-Based Assessment Aid (NEBA) System is a 15- to 20-minute noninvasive test that calculates the ratio of theta and beta waves. The theta/beta ratio has been shown to be higher in children and adolescents with ADHD. Read more.


Leave a Reply

You have to agree to the comment policy.

 

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares